***Background.*** *Enterobacteriaceae* play an important role in the pathogenesis of hospital infections worldwide. The Tigecycline Evaluation Surveillance Trial (TEST) examines the susceptibility of pathogens isolated from multiple infectious processes from patients in geographically diverse populations. With the increase of antimicrobial resistance, continued surveillance and susceptibility testing of pathogens isolated from patients in North America is essential. The purpose of this report is to examine the susceptibility of selected *Enterobacteriaceae* species isolated from patients in the United States and Canada from 2013.

***Methods.*** 4,010\* clinically significant *Enterobacteriaceae* sp. were obtained from patients with a wide spectrum of infections in patients in the United States and Canada. MICs were determined from 30 sites in 2013 using supplied broth microdilution panels. Susceptibility was interpreted according to CLSI guidelines.

***Results.*** The % susceptible for those 4,010 gram-negative bacilli against tigecycline and comparative antimicrobial agents is shown in the following table:

                          Drug % Susceptible                                             
  ----------------------- -------------------- ------ ------ ------ ------ ------ ------ ------
  *E. aerogenes* (272)    99.3                 3.7    98.9   77.6   97.4   98.5   86.0   97.4
  *E. asburiae* (102)     100                  5.9    100    80.4   97.1   100    91.2   100
  *E. cloacae* (688)      99.9                 4.7    95.6   70.4   93.9   98.6   82.1   94.9
  *E. coli* (1232)        99.8                 75.1   91.8   86.7   69.6   98.7   96.1   99.7
  *K. oxytoca* (259)      100                  87.6   98.1   90.0   95.0   99.2   91.1   98.8
  *K. pneumoniae* (957)   98.6                 85.6   90.9   84.1   86.7   95.2   89.7   95.0
  *S. marcescens* (462)   100                  1.5    98.7   85.7   91.6   98.1   96.5   96.3

AK=Amikacin, AC=Amoxicillin-Clavulanate, CPM=Cefepime, CFT=Ceftriaxone, LEVO=Levofloxacin, MER=Meropenem PT=Piperacillin-Tazobactam, TIG=Tigecycline

\*n\'s ≤ 15 are not reported

***Conclusion.*** *In vitro* tigecycline, meropenem and amikacin continue to be the most active antimicrobials against all *Enterobacteriaceae*. In the US and Canada the existence of levofloxacin resistant *E. coli* continues to be an issue. Additional monitoring of antimicrobial resistance in hospital pathogens in North America is warranted.
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